treating only the wt KRAS patients with panitumumab was €4.9 million, resulting in 41.7% savings. Total cost figures for the private sector were €8.7 million and €5 million respectively, resulting in 42.5% savings. CONCLUSIONS: By identifying the wt KRAS patients who are most likely to respond to treatment, panitumumab improves treatment outcomes and reduces unnecessary exposure to therapy, resulting in overall budget savings. Patient-level clinical benefits derived by panitumumab may lead to improvements in health outcomes and rational allocation of health care resources in Greece.
Durbecq V,Veys I, Majjaj S, Schobbens JC, Noterman D, Filippov V, Sirtaine N, Bourgeois P, Nogaret J, Larsimont D Institut Jules Bordet, Bruxelles, Belgium OBJECTIVES: A molecular assay (GeneSearch™ Breast Lymph Node (BLN) Assay, Veridex, LLC), CE marked and approved by the FDA, has been in clinical use at our institution for over 18 months to intra-operatively detect metastases 3 0.2 mm in the sentinel lymph nodes (SLNs) of breast cancer patients. After a small validation study (N = 78, sensitivity = 92.3%, specificity = 96.9%) the assay was adopted as the only intra-operative SLN test used at the Institut Jules Bordet. This is the first evaluation of the cost savings generated by the use of this BLN assay. METHODS: An economic evaluation was conducted in the first 300 patients in whom this BLN assay was used intra-operatively. The BLN assay results are used to make intra-operative decisions for axillary lymph node dissections (ALND) during the same surgery. We assessed the pathology, surgery & anesthesia, pharmacy, post-hospitalization, general, and total costs associated with patients having either: Surgery A = a lumpectomy + SLN + secondary ALND versus having: Surgery B = a lumpectomy + BLN + ALND. RESULTS: The total costs per patient for Surgery A was €3120, while for Surgery B it was €2210. Therefore, a difference of €910, were saved per patient when using the BLN assay, which represents a 29% cost savings. Since 58 patients avoided having a second surgery, the total cost savings accrued by the institution for the Belgian social security system as a result of using the BLN assay in this first cohort of 300 patients, was €52,780. CONCLUSIONS: The BLN assay was proved to be beneficial not only for our patients by reducing the need of second surgeries, it has also been demonstrated to be cost saving for the Belgian social security system. Its use at the Institut Jules Bordet in the first cohort of 300 patients has resulted in a cost savings of €52,780. To evaluate the cost-effectiveness of standard chemotherapy plus adjuvant trastuzumab treatment for one year compared to standard chemotherapy in patients with early breast cancer in Saudi Arabia. METHODS: A Markov model was adapted to estimate the costs and clinical outcomes (qualityadjusted life-years (QALYs) and life expectancy) associated with the progression of early breast cancer over patients' lifetimes. Patients transitioned through five health states according to probabilities reflecting the rates of disease progression observed in the HERA (HERceptin Adjuvant) trial. Total health care resource costs and utilization were estimated for each health state using values derived from a Saudi Arabian-specific survey. The analysis was done from the perspectives of the health care provider and society. The mean starting treatment age was assumed to be 30 years old, reflecting local demographics. Costs and outcomes were discounted at 3.5% per annum. Sensitivity analyses were performed. RESULTS: One-year adjuvant treatment with trastuzumab was estimated to increase life expectancy by 2.4 (4.9 undiscounted) years and quality-adjusted life years by 2.2 (4.3 undiscounted) QALYs, compared to standard chemotherapy. Over a patient's lifetime, total direct medical costs, including indirect costs (attributed to travel and time off work for patients and care-givers), were projected to increase by approximately SR48,452 (US$12,903) compared to chemotherapy alone. Treatment with trastuzumab was estimated to partially offset mean event and state costs compared to chemotherapy Abstracts A465
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